These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 18291366)
21. Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review. Sciriha GG; Sultana J; Borg J Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1423-1442. PubMed ID: 36308770 [TBL] [Abstract][Full Text] [Related]
22. Corneal Dystrophy Mutations Drive Pathogenesis by Targeting TGFBIp Stability and Solubility in a Latent Amyloid-forming Domain. Stenvang M; Schafer NP; Malmos KG; Pérez AW; Niembro O; Sormanni P; Basaiawmoit RV; Christiansen G; Andreasen M; Otzen DE J Mol Biol; 2018 Apr; 430(8):1116-1140. PubMed ID: 29524512 [TBL] [Abstract][Full Text] [Related]
23. Genotype of lattice corneal dystrophy (R124C mutation in TGFBI) in a patient presenting with features of Avellino corneal dystrophy. Lisch W; Moller HU Cornea; 2011 Aug; 30(8):949; author reply 949-50. PubMed ID: 21617530 [No Abstract] [Full Text] [Related]
24. A novel mutation of the TGFBI gene causing a lattice corneal dystrophy with deep stromal involvement. Kawasaki S; Yagi H; Yamasaki K; Matsuda A; Takeda K; Kinoshita S Br J Ophthalmol; 2011 Jan; 95(1):150-1. PubMed ID: 20974628 [No Abstract] [Full Text] [Related]
25. Novel TGFBI mutation p.(Leu558Arg) in a lattice corneal dystrophy patient. Dudakova L; Palos M; Jirsova K; Skalicka P; Dundr P; Liskova P Ophthalmic Genet; 2016 Dec; 37(4):473-474. PubMed ID: 27028151 [No Abstract] [Full Text] [Related]
26. Mutation effects on FAS1 domain 4 based on structure and solubility. Kim D; Chong SH; Shin S; Ham S Biochim Biophys Acta Proteins Proteom; 2022 Mar; 1870(3):140746. PubMed ID: 34942360 [TBL] [Abstract][Full Text] [Related]
35. Genetics of the corneal dystrophies: what we have learned in the past twenty-five years. Bron AJ Cornea; 2000 Sep; 19(5):699-711. PubMed ID: 11009322 [TBL] [Abstract][Full Text] [Related]
36. Effect of osmolytes on in-vitro aggregation properties of peptides derived from TGFBIp. Venkatraman A; Murugan E; Lin SJ; Peh GSL; Rajamani L; Mehta JS Sci Rep; 2020 Mar; 10(1):4011. PubMed ID: 32132634 [TBL] [Abstract][Full Text] [Related]
37. Unusual phenotype of an individual with the R124C mutation in the TGFBI gene. Morishige N; Chikama T; Ishimura Y; Nishida T; Takahashi M; Mashima Y Arch Ophthalmol; 2004 Aug; 122(8):1224-7. PubMed ID: 15302666 [No Abstract] [Full Text] [Related]
38. Lattice Corneal Dystrophy: a report of two cases in twin sisters due to 3 mutations (T1620C, C1416T, A1924G) in the TGFBI (BIGH3) gene. Costagliola C; Romano V; Cifariello F; Aceto F; Porcellini A Clin Ter; 2014; 165(1):e73-5. PubMed ID: 24589966 [TBL] [Abstract][Full Text] [Related]
39. Widening the view. Meitinger T Nat Genet; 1997 Mar; 15(3):224-5. PubMed ID: 9054926 [No Abstract] [Full Text] [Related]
40. 4-Phenylbutyric acid reduces mutant-TGFBIp levels and ER stress through activation of ERAD pathway in corneal fibroblasts of granular corneal dystrophy type 2. Choi SI; Lee E; Jeong JB; Akuzum B; Maeng YS; Kim TI; Kim EK Biochem Biophys Res Commun; 2016 Sep; 477(4):841-846. PubMed ID: 27373828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]